Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy

JAAD Case Reports

Volumn 2, Issue 3, 2016, Pages 264-268

  Suozzi, Kathleen C ^a   Stahl, Maximilian ^a   Ko, Christine J ^a   Chiang, Anne ^a   Gettinger, Scott N ^a   Siegel, Mark D ^a   Bunick, Christopher G ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Immune related adverse events; Immunotherapy; Lung cancer; Sarcoidosis

Indexed keywords

CLOBETASOL; DIPHENHYDRAMINE; IPILIMUMAB; NIVOLUMAB; TRIAMCINOLONE;

ADULT; ARTICLE; BRAIN DAMAGE; BRONCHOSCOPY; BRONCHUS BIOPSY; CANCER IMMUNOTHERAPY; CASE REPORT; FEMALE; FOLLOW UP; GAMMA KNIFE RADIOSURGERY; GENE REARRANGEMENT; HUMAN; IMMUNE RELATED SARCOIDOSIS; LUNG ADENOCARCINOMA; LYMPH NODE METASTASIS; MACULOPAPULAR RASH; MIDDLE AGED; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADIATION NECROSIS; SARCOIDOSIS;

EID: 84978128466     PISSN: None     EISSN: 23525126     Source Type: Journal    
DOI: 10.1016/j.jdcr.2016.05.002     Document Type: Article

References (18)

1. Larkin J., Chiarion-Sileni V., Gonzalez R., et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015, 373(1):23-34.
2. Reule R.B., North J.P. Cutaneous and pulmonary sarcoidosis-like reaction associated with ipilimumab. J Am Acad Dermatol 2013, 69(5):e272-e273.
3. Eckert A., Schoeffler A., Dalle S., Phan A., Kiakouama L., Thomas L. Anti-CTLA4 monoclonal antibody induced sarcoidosis in a metastatic melanoma patient. Dermatology 2009, 218(1):69-70.
4. Vogel W.V., Guislain A., Kvistborg P., Schumacher T.N., Haanen J.B., Blank C.U. Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission. J Clin Oncol 2012, 30(2):e7-e10.
5. van den Eertwegh A.J., Versluis J., van den Berg H.P., et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012, 13(5):509-517.
6. Wilgenhof S., Morlion V., Seghers A.C., et al. Sarcoidosis in a patient with metastatic melanoma sequentially treated with anti-CTLA-4 monoclonal antibody and selective BRAF inhibitor. Anticancer Res 2012, 32(4):1355-1359.
7. Berthod G., Lazor R., Letovanec I., et al. Pulmonary sarcoid-like granulomatosis induced by ipilimumab. J Clin Oncol 2012, 30(17):e156-e159.
8. Brahmer J.R., Tykodi S.S., Chow L.Q., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012, 366(26):2455-2465.
9. Tissot C., Carsin A., Freymond N., Pacheco Y., Devouassoux G. Sarcoidosis complicating anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody biotherapy. Eur Respir J 2013, 41(1):246-247.
10. Murphy K.P., Kennedy M.P., Barry J.E., O'Regan K.N., Power D.G. New-onset mediastinal and central nervous system sarcoidosis in a patient with metastatic melanoma undergoing CTLA4 monoclonal antibody treatment. Oncol Res Treat 2014, 37(6):351-353.
11. Andersen R., Norgaard P., Al-Jailawi M.K., Svane I.M. Late development of splenic sarcoidosis-like lesions in a patient with metastatic melanoma and long-lasting clinical response to ipilimumab. Oncoimmunology 2014, 3(8):e954506.
12. Toumeh A., Sakhi R., Shah S., Arudra S.K., De Las Casas L.E., Skeel R.T. Ipilimumab-Induced Granulomatous Disease Occurring Simultaneously With Disease Progression in a Patient With Metastatic Melanoma. Am J Ther April 30, 2015, [Epub ahead of print].
13. Teulings H.E., Limpens J., Jansen S.N., et al. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol 2015, 33(7):773-781.
14. Hughes J., Vudattu N., Sznol M., et al. Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diabetes Care 2015, 38(4):e55-e57.
15. Choi J.N. Dermatologic adverse events to chemotherapeutic agents, Part 2: BRAF inhibitors, MEK inhibitors, and ipilimumab. Semin Cutan Med Surg 2014, 33(1):40-48.
16. Kochupurakkal N.M., Kruger A.J., Tripathi S., et al. Blockade of the programmed death-1 (PD1) pathway undermines potent genetic protection from type 1 diabetes. PLoS One 2014, 9(2):e89561.
17. Chen E.S., Moller D.R. Etiologies of Sarcoidosis. Clin Rev All Immunol 2015, 49(1):6-18.
18. Beutler B.D., Cohen P.R. Sarcoidosis in Melanoma Patients: Case Report and Literature Review. Cancers 2015, 7(2):1005-1021.